Organic compounds
The invention relates to particular substituted deuterated heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-HT 2A receptor, serotonin transporter (SERT) and/or pathways involving dopamine D 1 /D 2 receptor signaling systems, and/or the treatment of residual symptoms.
1 . A compound of formula II,
wherein R 1 and R 2 are both D, in solid mono-tosylate salt form.
2 . The compound according to claim 1 , wherein the compound has greater than 90% incorporation of deuterium at the indicated deuterium positions of the structure.
3 . A pharmaceutical composition comprising the compound according to claim 1 in combination or association with a pharmaceutically acceptable diluent or carrier.
4 . The compound according to claim 1 , wherein the compound of Formula II is in crystalline form.
5 . The compound according to claim 1 , wherein the compound of Formula II is in amorphous form.
6 . The compound according to claim 1 , wherein the compound has greater than 95% incorporation of deuterium at the indicated deuterium positions of the structure.
7 . The pharmaceutical composition according to claim 3 , wherein the composition is a tablet or capsule.
8 . The compound according to claim 4 , wherein the compound has greater than 90% incorporation of deuterium at the indicated deuterium positions of the structure.
9 . The compound according to claim 4 , wherein the compound has greater than 95% incorporation of deuterium at the indicated deuterium positions of the structure.
10 . A pharmaceutical composition comprising the compound according to claim 4 in combination or association with a pharmaceutically acceptable diluent or carrier.
11 . The pharmaceutical composition according to claim 10 , wherein the composition is a tablet or capsule.
12 . The compound according to claim 5 , wherein the compound has greater than 90% incorporation of deuterium at the indicated deuterium positions of the structure.
13 . The compound according to claim 5 , wherein the compound has greater than 95% incorporation of deuterium at the indicated deuterium positions of the structure.
14 . A pharmaceutical composition comprising the compound according to claim 5 in combination or association with a pharmaceutically acceptable diluent or carrier.
15 . The pharmaceutical composition according to claim 14 , wherein the composition is a tablet or capsule.